Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Jost Philipp |

** = Publikationen gelistet in SCI/SSCI/Pubmed

2023

Beiträge in Fachzeitschriften

** Koschmieder, S; Isfort, S; Wolf, D; Heidel, FH; Hochhaus, A; Schafhausen, P; Griesshammer, M; Wolleschak, D; Platzbecker, U; Dohner, K; Jost, PJ; Parmentier, S; Schaich, M; von Bubnoff, N; Stegelmann, F; Maurer, A; Crysandt, M; Gezer, D; Kortmann, M; Franklin, J; Frank, J; Hellmich, M; Brummendorf, TH Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
ANN HEMATOL. 2023; Doi: 10.1007/s00277-022-05080-7 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2022

** Aftahy, AK; Barz, M; Lange, N; Baumgart, L; Thunstedt, C; Eller, MA; Wiestler, B; Bernhardt, D; Combs, SE; Jost, PJ; Delbridge, C; Liesche-Starnecker, F; Meyer, B; Gempt, J The Impact of Postoperative Tumor Burden on Patients With Brain Metastases
FRONT ONCOL. 2022; 12: 869764 Doi: 10.3389/fonc.2022.869764 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Balihodzic, A; Prinz, F; Dengler, MA; Calin, GA; Jost, PJ; Pichler, M Non-coding RNAs and ferroptosis: potential implications for cancer therapy.
Cell Death Differ. 2022; 29(6):1094-1106 Doi: 10.1038/s41418-022-00998-x [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Barth, DA; Stanzer, S; Spiegelberg, J; Bauernhofer, T; Absenger, G; Posch, F; Lipp, R; Halm, M; Szkandera, J; Balic, M; Gerger, A; Smolle, MA; Hutterer, GC; Klec, C; Jost, PJ; Kargl, J; Stradner, M; Pichler, M Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Cancer Med. 2022; 11(16):3074-3083 Doi: 10.1002/cam4.4675 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Barth, DA; Stanzer, S; Spiegelberg, JA; Bauernhofer, T; Absenger, G; Szkandera, J; Gerger, A; Smolle, MA; Hutterer, GC; Ahyai, SA; Madl, T; Posch, F; Riedl, JM; Klec, C; Jost, PJ; Kargl, J; Stradner, MH; Pichler, M Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Front Immunol. 2022; 13: 840207 Doi: 10.3389/fimmu.2022.840207 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Baumgart, L; Barz, M; Delbridge, C; Aftahy, AK; Janssen, IK; Jost, PJ; Ryang, YM; Meyer, B; Gempt, J Spinal Lesions as Clinical Manifestations of Plasma Cell Neoplasia
CURR ONCOL. 2022; 29(9): 6236-6244. Doi: 10.3390/curroncol29090490 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Dill, V; Wagner, CV; Keller, EC; Fernandez-Hernandez, FJ; Shoumariyeh, K; Odinius, TO; Buschhorn, L; Hauch, RT; Suren, C; Hecker, JS; Herhaus, P; Sandherr, M; Schmidt, B; Slotta-Huspenina, J; Bassermann, F; Höckendorf, U; Jilg, S; Branca, C; Vosberg, S; Jost, PJ Elevated RIPK3 correlates with disease burden in myelofibrosis.
Blood Adv. 2022; Doi: 10.1182/bloodadvances.2021006838
PubMed FullText FullText_MUG

 

** Fluhrer, H; Hutterer, GC; Golbeck, S; Stidl, M; Niedrist, T; Pichler, R; Mischinger, J; Seles, M; Mannweiler, S; Spiegelberg, J; Bauernhofer, T; Jost, PJ; Ahyai, S; Zigeuner, R; Pichler, M; Barth, DA Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.
Ther Adv Med Oncol. 2022; 14: 17588359221134065 Doi: 10.1177/17588359221134065 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

** Heilig, CE; Lassmann, A; Mughal, SS; Mock, A; Pirmann, S; Teleanu, V; Renner, M; Andresen, C; Kohler, BC; Aybey, B; Bauer, S; Siveke, JT; Hamacher, R; Folprecht, G; Richter, S; Schrock, E; Brandts, CH; Ahrens, M; Hohenberger, P; Egerer, G; Kindler, T; Boerries, M; Illert, AL; von Bubnoff, N; Apostolidis, L; Jost, PJ; Westphalen, CB; Weichert, W; Keilholz, U; Klauschen, F; Beck, K; Winter, U; Richter, D; Mohrmann, L; Bitzer, M; Schulze-Osthoff, K; Brors, B; Mechtersheimer, G; Kreutzfeldt, S; Heining, C; Lipka, DB; Stenzinger, A; Schlenk, RF; Horak, P; Glimm, H; Hubschmann, D; Frohling, S Gene expression-based prediction of pazopanib efficacy in sarcoma
EUR J CANCER. 2022; 172: 107-118. Doi: 10.1016/j.ejca.2022.05.025
Web of Science PubMed FullText FullText_MUG

 

** Jahn, A; Rump, A; Widmann, TJ; Heining, C; Horak, P; Hutter, B; Paramasivam, N; Uhrig, S; Gieldon, L; Drukewitz, S; Kubler, A; Bermudez, M; Hackmann, K; Porrmann, J; Wagner, J; Arlt, M; Franke, M; Fischer, J; Kowalzyk, Z; William, D; Weth, V; Oster, S; Frohlich, M; Hullein, J; Gonzalez, CV; Kreutzfeldt, S; Mock, A; Heilig, CE; Lipka, DB; Mohrmann, L; Hanf, D; Oles, M; Teleanu, V; Allgauer, M; Ruhnke, L; Kutz, O; Knurr, A; Lassmann, A; Endris, V; Neumann, O; Penzel, R; Beck, K; Richter, D; Winter, U; Wolf, S; Pfutze, K; Georg, C; Meissburger, B; Buchhalter, I; Augustin, M; Aulitzky, WE; Hohenberger, P; Kroiss, M; Schirmacher, P; Schlenk, RF; Keilholz, U; Klauschen, F; Folprecht, G; Bauer, S; Siveke, JT; Brandts, CH; Kindler, T; Boerries, M; Illert, AL; von Bubnoff, N; Jost, PJ; Metzeler, KH; Bitzer, M; Schulze-Osthoff, K; von Kalle, C; Brors, B; Stenzinger, A; Weichert, W; Hubschmann, D; Frohling, S; Glimm, H; Schrock, E; Klink, B Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers
ANN ONCOL. 2022; 33(11): 1186-1199. Doi: 10.1016/j.annonc.2022.07.008
Web of Science PubMed FullText FullText_MUG

 

** Jahn, SW; Jost, PJ Challenges in integrating molecular profiles into clinical cancer care
MEMO-MAG EUR MED ONC. 2022; Doi: 10.1007/s12254-022-00838-1
Web of Science FullText FullText_MUG

 

** Maisel, F; Smolle, MA; Mollnar, S; Riedl, JM; Barth, DA; Seles, M; Terbuch, A; Rossmann, CH; Eisner, F; Mannweiler, S; Hutterer, G; Zigeuner, R; Pummer, K; Smolle-Jüttner, FM; Lindenmann, J; Stotz, M; Gerger, A; Jost, PJ; Bauernhofer, T; Pichler, M; Posch, F Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis.
Clin Genitourin Cancer. 2022; 20(4):344-353 Doi: 10.1016/j.clgc.2022.03.010
Web of Science PubMed FullText FullText_MUG

 

** Meinhardt, AL; Munkhbaatar, E; Höckendorf, U; Dietzen, M; Dechant, M; Anton, M; Jacob, A; Steiger, K; Weichert, W; Brcic, L; McGranahan, N; Branca, C; Kaufmann, T; Dengler, MA; Jost, PJ The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner.
Oncogene. 2022; 41(9):1376-1382 Doi: 10.1038/s41388-021-02161-1 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Posch, F; Niedrist, T; Glantschnig, T; Firla, S; Moik, F; Kolesnik, E; Wallner, M; Verheyen, N; Jost, PJ; Zirlik, A; Pichler, M; Balic, M; Rainer, PP Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer.
Front Cardiovasc Med. 2022; 9: 933428 Doi: 10.3389/fcvm.2022.933428 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Reissig, TM; Uhrig, S; Jost, PJ; Luchini, C; Vicentini, C; Liffers, ST; Allgauer, M; Adsay, V; Scarpa, A; Lawlor, RT; Frohling, S; Stenzinger, A; Kloppel, G; Schildhaus, HU; Siveke, JT MCL1 as putative target in pancreatoblastoma
VIRCHOWS ARCH. 2022; Doi: 10.1007/s00428-022-03349-w [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Riedl, JM; Schwarzenbacher, E; Moik, F; Horvath, L; Gantschnigg, A; Renneberg, F; Posch, F; Barth, DA; Stotz, M; Pichler, M; Hatzl, S; Fandler-Höfler, S; Gressenberger, P; Gary, T; Jost, PJ; Greil, R; Ay, C; Djanani, A; Gerger, A; Schlick, K Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Thromb Haemost. 2022; 122(4):633-645 Doi: 10.1055/a-1548-4847
Web of Science PubMed FullText FullText_MUG

 

** Suppan, C; Graf, R; Jahn, S; Zhou, Q; Klocker, EV; Bartsch, R; Terbuch, A; Kashofer, K; Regitnig, P; Lindenmann, J; Posch, F; Gerritsmann, H; Jost, PJ; Heitzer, E; Dandachi, N; Balic, M Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
Br J Cancer. 2022; 126(3):456-463 Doi: 10.1038/s41416-021-01601-9 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Terbuch, A; Posch, F; Bauernhofer, T; Jost, PJ; Partl, R; Stranzl-Lawatsch, H; Baciarello, G; Fizazi, K; Giannatempo, P; Verzoni, E; Sweeney, C; Ravi, P; Tran, B; Basso, U; White, J; Vincenzi, B; Oing, C; Cutuli, HJ; Dieckmann, KP; Gamulin, M; Chovanec, M; Fankhauser, CD; Heidenreich, A; Mohamad, O; Thibault, C; Fischer, S; Gillessen, S, , International, Germ, Cell, Cancer, Collaborative, Group Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy.
Int J Radiat Oncol Biol Phys. 2022; 113(4):825-832 Doi: 10.1016/j.ijrobp.2022.03.021
Web of Science PubMed FullText FullText_MUG

 

** Wahida, A; Buschhorn, L; Frohling, S; Jost, PJ; Schneeweiss, A; Lichter, P; Kurzrock, R The coming decade in precision oncology: six riddles
NAT REV CANCER. 2022; Doi: 10.1038/s41568-022-00529-3
Web of Science PubMed FullText FullText_MUG

 

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

** Allmendinger, F; Agrawal, D; Dietzen, M; Vosberg, S; Munkhbaatar, E; McGranahan, N; Jost, P Inflammatory cell death acts as tumor suppressor in lung adenocarcinoma
INTERNIST. 2022; 63(SUPPL 3):338-339. [Oral Communication]
Web of Science

 

** Brcic, L; Zacharias, M; Konjic, S; Kashofer, K; Absenger, G; Jost, PJ; Wurm, R; Lindenmann, J; Terbuch, A Molecular testing in lung squamous cell carcinoma using DNA- and RNA-based next-generation sequencing: A singlecenter experience
ANN ONCOL. 2022; 38(9): S1557-S1557. Doi: 10.1016/j.annonc.2022.10.344 [Poster]
Web of Science FullText FullText_MUG

 

** Keller, EC; Jost, PJ; Schwamborn, K; Weichert, W; Horn, T; Slotta-Huspenina, J Mixed Lineage Kinase Domain-like Protein (MLKL) in Primary Resected Bladder Cancer: Expression, Prognostic Role and Correlations with the Immune Environment
MODERN PATHOL. 2022; 35(SUPPL 2): 613-613. [Poster]
Web of Science

 

** Keller, EC; Jost, PJ; Schwamborn, K; Weichert, W; Horn, T; Slotta-Huspenina, J Mixed Lineage Kinase Domain-like Protein (MLKL) in Primary Resected Bladder Cancer: Expression, Prognostic Role and Correlations with the Immune Environment
LAB INVEST. 2022; 102(SUPPL 1): 613-613. [Poster]
Web of Science

 

** Moik, F; Riedl, J; Barth, D; Chan, WSE; Wiedemann, S; Holler, C; Fuereder, T; Jost, P; Pabinger, I; Preusser, M; Ay, C Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors
BLOOD. 2022; 140: 1250-1251. Doi: 10.1182/blood-2022-160087 [Oral Communication]
Web of Science FullText FullText_MUG

 

** Riedl, JM; Barth, D; Steinlechner, S; Moik, F; Posch, F; Schlintl, V; Mayer, MC; Sandner, AM; Berton, F; Koch, L; John, N; Wurm, R; Pichler, M; Absenger, G; Jost, PJ; Wohlkonig, C; Richtig, E; Winder, T; Gerger, A; Terbuch, A Early CRP Kinetics after Initiation of Immune Checkpoint Inhibitors is a predictive Biomarker for Treatment Response independent of the Tumor Antity
ONCOL RES TREAT. 2022; 45(SUPPL 2):228-228.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien. [Poster]
Web of Science

 

** Schranz, A; Sternad, C; Mischinger, HJ; Wagner, D; Jost, PJ; Riedl, J; Wolfler, A; Pieber, T; Sourij, H; Aberer, F Incidence of diabetes and its impact on survival after pancreatic tumor surgery - a retrospective data analysis
WIEN KLIN WOCHENSCHR. 2022; 134(SUPPL 4):258-259.-Jahrestagung der Österreichischen Diabetesgesellschaft ; [Poster]
Web of Science

 

** Zacharias, M; Konjic, S; Absenger, G; Hochmair, MJ; Fabikan, H; Weinlinger, C; Illini, O; Jost, PJ; Schlintl, V; Wurm, R; Lindenmann, J; Fediuk, M; Brcic, L; Terbuch, A Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas
J THORAC ONCOL. 2022; 17(9): S201-S202. [Poster]
Web of Science

 

Barth, D; Stradner, M; Hutterer, H; Spiegelberg, J; Bauernhofer, T; Absenger, G; Jost, P; Pichler, M Blood-based B-cell subtypes as predictors of treatment response during treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study.
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology 2022. 2022; -OeGHO Frühjahrstagung 2022; APR 8-10, 2022; Graz, AUSTRIA. [Poster]

 

Huemer, M; Jahn-Kuch D; Hofmann, G; Andritsch, E; Farkas C; Schaupp, W; Masel EK; Jost JP; Pichler M Trends of public interest in palliative care, euthanasia, and advanced health care directives in Austria, Germany, and Switzerland using big data from Google
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology. 2022; 22(3):17-17.-OeGHO & AHOP Frühjahrstagung; APR 8-10, 2022; Graz, AUSTRIA. [Poster]
FullText

 

Krajina, K; Kapeller, A; Dengler, M; Jost, P; Pichler, M; Klec, C The long non-coding RNA NORAD and its relevance on PARP inhibitor sensitivity in triple negative breast cancer
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology. 2022; -OeGHO- & AHOP-Frühjahrstagung 2022; APR 8-10, 2022; Graz, AUSTRIA. [Poster]

 

Lindenmann, J; Fink-Neuboeck, N; Fediuk, M; Porubsky, Ch; Absenger, G; Mykoliuk, I; Brcic, L; Anegg, U; Maier, A; Jost, P; Smolle, J; Smolle-Juettner, FM Recurrence and survival following surgery of T3 esophageal carcinoma with curative intent. Role of circumferential resection margin.
European Surgrey- ACA. 2022; 54: 50-50.-63. Österreichischer Chirurgenkongress; JUN 15-17, 2022; Graz, AUSTRIA. [Oral Communication]

 

2021

Beiträge in Fachzeitschriften

** Barz, M; Aftahy, K; Janssen, I; Ryang, YM; Prokop, G; Combs, SE; Jost, PJ; Meyer, B; Gempt, J Spinal Manifestation of Malignant Primary (PLB) and Secondary Bone Lymphoma (SLB).
CURR ONCOL. 2021; 28(5): 3891-3899. Doi: 10.3390/curroncol28050332 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Carlet, M; Völse, K; Vergalli, J; Becker, M; Herold, T; Arner, A; Senft, D; Jurinovic, V; Liu, WH; Gao, Y; Dill, V; Fehse, B; Baldus, CD; Bastian, L; Lenk, L; Schewe, DM; Bagnoli, JW; Vick, B; Schmid, JP; Wilhelm, A; Marschalek, R; Jost, PJ; Miething, C; Riecken, K; Schmidt-Supprian, M; Binder, V; Jeremias, I In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets.
Nat Commun. 2021; 12(1): 5655 Doi: 10.1038/s41467-021-25963-z [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Horak, P; Heining, C; Kreutzfeldt, S; Hutter, B; Mock, A; Hüllein, J; Fröhlich, M; Uhrig, S; Jahn, A; Rump, A; Gieldon, L; Möhrmann, L; Hanf, D; Teleanu, V; Heilig, CE; Lipka, DB; Allgäuer, M; Ruhnke, L; Laßmann, A; Endris, V; Neumann, O; Penzel, R; Beck, K; Richter, D; Winter, U; Wolf, S; Pfütze, K; Geörg, C; Meißburger, B; Buchhalter, I; Augustin, M; Aulitzky, WE; Hohenberger, P; Kroiss, M; Schirmacher, P; Schlenk, RF; Keilholz, U; Klauschen, F; Folprecht, G; Bauer, S; Siveke, JT; Brandts, CH; Kindler, T; Boerries, M; Illert, AL; von, Bubnoff, N; Jost, PJ; Spiekermann, K; Bitzer, M; Schulze-Osthoff, K; von, Kalle, C; Klink, B; Brors, B; Stenzinger, A; Schröck, E; Hübschmann, D; Weichert, W; Glimm, H; Fröhling, S Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.
Cancer Discov. 2021; 11(11): 2780-2795. Doi: 10.1158/2159-8290.CD-21-0126
Web of Science PubMed FullText FullText_MUG

 

** Huemer, M; Jahn-Kuch, D; Hofmann, G; Andritsch, E; Farkas, C; Schaupp, W; Masel, EK; Jost, PJ; Pichler, M Trends and Patterns in the Public Awareness of Palliative Care, Euthanasia, and End-of-Life Decisions in 3 Central European Countries Using Big Data Analysis From Google: Retrospective Analysis.
J Med Internet Res. 2021; 23(9): e28635 Doi: 10.2196/28635 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Kricheldorf, K; Döhner, K; Stegelmann, F; Jost, PJ; Lang, F; Radsak, M; Hansen, R; Heuer, V; Röhrig, R; Brümmendorf, TH; Koschmieder, S; Isfort, S Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN.
LEUKEMIA RES. 2021; 110: 106646 Doi: 10.1016/j.leukres.2021.106646 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Liotta, L; Lange, S; Maurer, HC; Olive, KP; Braren, R; Pfarr, N; Burger, S; Muckenhuber, A; Jesinghaus, M; Steiger, K; Weichert, W; Friess, H; Schmid, R; Algül, H; Jost, PJ; Ramser, J; Fischer, C; Quante, AS; Reichert, M; Quante, M PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer.
JCI Insight. 2021; 6(8): Doi: 10.1172/jci.insight.141532 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Müller, M; Posch, F; Kiem, D; Barth, D; Horvath, L; Stotz, M; Schaberl-Moser, R; Pichler, M; Greil, R; Jost, PJ; Seeber, A; Amann, A; Schlick, K; Gerger, A; Riedl, JM Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.
Ther Adv Med Oncol. 2021; 13: 17588359211039930 Doi: 10.1177/17588359211039930 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Odinius, TO; Buschhorn, L; Wagner, C; Hauch, RT; Dill, V; Dechant, M; Buck, MC; Shoumariyeh, K; Moog, P; Schwaab, J; Reiter, A; Brockow, K; Götze, K; Bassermann, F; Höckendorf, U; Branca, C; Jost, PJ; Jilg, S Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies.
J CANCER RES CLIN. 2021; Doi: 10.1007/s00432-021-03827-9 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Pichler, T; Rohrmoser, A; Letsch, A; Westphalen, CB; Keilholz, U; Heinemann, V; Lamping, M; Jost, PJ; Riedmann, K; Herschbach, P; Goerling, U Information, communication, and cancer patients' trust in the physician: what challenges do we have to face in an era of precision cancer medicine?
Support Care Cancer. 2021; 29(4):2171-2178 Doi: 10.1007/s00520-020-05692-7 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Smolle, E; Taucher, V; Lindenmann, J; Jost, PJ; Pichler, M Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer.
Cancers (Basel). 2021; 13(4): Doi: 10.3390/cancers13040699 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Suppan, C; Posch, F; Mueller, HD; Mischitz, N; Steiner, D; Klocker, EV; Setaffy, L; Bargfrieder, U; Hammer, R; Hauser, H; Jost, PJ; Dandachi, N; Lax, S; Balic, M Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity.
Cancers (Basel). 2021; 13(10): Doi: 10.3390/cancers13102492 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Wahida, A; Müller, M; Hiergeist, A; Popper, B; Steiger, K; Branca, C; Tschurtschenthaler, M; Engleitner, T; Donakonda, S; De, Coninck, J; Öllinger, R; Pfautsch, MK; Müller, N; Silva, M; Usluer, S; Oberg, ET; Böttcher, JP; Pfarr, N; Anton, M; Slotta-Huspenina, JB; Nerlich, AG; Madl, T; Basic, M; Bleich, A; Berx, G; Ruland, J; Knolle, PA; Rad, R; Adolph, TE; Vandenabeele, P; Kanegane, H; Gessner, A; Jost, PJ; Yabal, M XIAP restrains TNF-driven intestinal inflammation and dysbiosis by promoting innate immune responses of Paneth and dendritic cells.
Sci Immunol. 2021; 6(65): eabf7235 Doi: 10.1126/sciimmunol.abf7235
Web of Science PubMed FullText FullText_MUG

 

** Wang, X; Ros, U; Agrawal, D; Keller, EC; Slotta-Huspenina, J; Dill, V; Shen, B; Shi, R; Herold, T; Belka, C; Mishra, R; Bassermann, F; Garcia-Saez, AJ; Jost, PJ Correction: MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF.
Cell Death Differ. 2021; Doi: 10.1038/s41418-021-00826-8 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Wang, X; Ros, U; Agrawal, D; Keller, EC; Slotta-Huspenina, J; Dill, V; Shen, B; Shi, R; Herold, T; Belka, C; Mishra, R; Bassermann, F; Garcia-Saez, AJ; Jost, PJ MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF.
CELL DEATH DIFFER. 2021; Doi: 10.1038/s41418-021-00811-1 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

** Allmendinger, F; Agrawal, D; Dietzen, M; Vosberg, S; Munkhbaatar, E; Branca, C; McGranahan, N; Jost, PJ RIPK3 downregulation in lung cancer alters the tumor immune micro-environment supporting tumor progression
ONCOL RES TREAT. 2021; 44: 51-52.
Web of Science

 

** Allmendinger, F; Agrawal, D; Dietzen, M; Vosberg, S; Munkhbaatar, E; McGranahan, N; Jost, PJ Necroptosis establishes an inflammatory tumor immune microenvironment acting as tumor suppressor in lung adenocarcinoma
ANN ONCOL. 2021; 32: S945-S945. Doi: 10.1016/j.annonc.2021.08.1788 [Poster]
Web of Science FullText FullText_MUG

 

** Dill, V; Wagner, C; Keller, E; Shoumariyeh, K; Odinius, T; Buschhorn, L; Suren, C; Hecker, J; Herhaus, P; Sandherr, M; Schmidt, B; Slotta-Huspenina, J; Bassermann, F; Hockendorf, U; Branca, C; Jilg, S; Jost, PJ RIPK3-dependent necroinflammation as a disease promoting mechanism in human myelofibrosis
ONCOL RES TREAT. 2021; 44: 161-161.
Web of Science

 

** Jost, PJ; Munkhbaatar, E; Dietzen, M; Branca, C; McGranahan, N Clonal evolution in lung cancer highlights MCL-1 gains as therapeutic target in lung adenocarcinoma
J THORAC ONCOL. 2021; 16(4):S704-S704. [Poster]
Web of Science

 

** Lorch, M; Pfirrmann, M; Fabisch, C; Oberle, L; Kohn, D; Kohlbrenner, K; Brummendorf, TH; Burchert, A; Krause, SW; le Coutre, P; Hanel, M; Franke, GN; Stegelmann, F; Radsak, M; Kunzmann, V; Jost, PJ; Hofmann, WK; Hochhaus, A; Saussele, S Health-related quality of life (HRQoL) in CML-patients at diagnosis compared to general population
ONCOL RES TREAT. 2021; 44: 71-72.
Web of Science

 

** Terbuch, A; Absenger, G; Steinlechner, S; Jost, P; Wurm, R; Wohlkonig, C; Olschewski, H; Richtig, E; Koch, L; Winder, T; Woll, E; Gerger, A Autriche - AUsTrian Registry for Immune CHEckpoint inhibitors
ONCOL RES TREAT. 2021; 44: 229-229. [Poster]
Web of Science

 

Klocker, EV; Posch, F; Suppan, C; Mischitz, N; Dengler, L; Steiner, D; Müller, HD; Jost, P; Dandachi, N; Balic, M Histopathological features and prognosis of early lobular breast cancer
Oncology Research and Treatment, Vol. 44, Suppl. 2, 2021. 2021; -Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie ; OCT 1-4, 2021; Berlin, GERMANY. [Poster]

 

Smolle, M; Woelfel, J; Acem, I; Van De Sande, MAJ; Jeys, L; Bonekamp, H; Pollock, R; Keller, J; Tunn, PU; Haas, R; Van Ginkel, RJ; Verhoef, C; Posch, F; Liegl-Atzwanger, B; Moustafa-Hubmer, D; Jost, PJ; Leithner, A; Szkandera J Neoadjuvant and adjuvant radiotherapy decreases the risk of local recurrence and adjuvant chemotherapy improves overall survival in a multicentre cohort of 2184 extremity soft tissue sarcoma patients
CTOS Abstract Book. 2021; -CTOS (Connective Tissue Oncology Society); NOV 10-13; Toronto, CANADA. [Oral Communication]

 

Smolle, MA; Woelfel, J; Acem, I; van de Sande, M; Jeys, L; Bonekamp, H; Pollock, R; Keller, J; Tunn, PU; Haas, R; van Ginkel, RJ; Verhoef, C; Posch, F; Liegl-Atzwanger, B; Moustafa-Hubmer, D; Jost, P; Leithner, A; Szkandera, J Effect of Neoadjuvant and Adjuvant Radiotherapy on Local Recurrence, Distant Metastasis, and Overall Survival in Extremity Soft Tissue Sarcoma.
Abstract Book of the EMSOS 2021. 2021; -EMSOS Annual Meeting 2021; DEC 1-3, 2021; Graz, AUSTRIA. [Onlinepräsentation]

 

2020

Beiträge in Fachzeitschriften

** Crodel, CC; Jentsch-Ullrich, K; Koschmieder, S; Kämpfe, D; Griesshammer, M; Döhner, K; Jost, PJ; Wolleschak, D; Isfort, S; Stegelmann, F; Jilg, S; Hofmann, V; Auteri, G; Rachow, T; Ernst, P; Brioli, A; von Lilienfeld-Toal, M; Hochhaus, A; Palandri, F; Heidel, FH Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study.
Leukemia. 2020; 34(7):1949-1953 Doi: 10.1038/s41375-020-0890-1 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Crodel, CC; Jentsch-Ullrich, K; Koschmieder, S; Kämpfe, D; Griesshammer, M; Döhner, K; Jost, PJ; Wolleschak, D; Isfort, S; Stegelmann, F; Jilg, S; Hofmann, V; Auteri, G; Rachow, T; Ernst, P; Brioli, A; von Lilienfeld-Toal, M; Hochhaus, A; Palandri, F; Heidel, FH Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study.
Leukemia. 2020; 34(11): 3106-3106. Doi: 10.1038/s41375-020-0970-2 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Dill, V; Kauschinger, J; Hauch, RT; Buschhorn, L; Odinius, TO; Müller-Thomas, C; Mishra, R; Kyncl, MC; Schmidt, B; Prodinger, PM; Hempel, D; Bellos, F; Höllein, A; Kern, W; Haferlach, T; Slotta-Huspenina, J; Bassermann, F; Peschel, C; Götze, KS; Waizenegger, IC; Höckendorf, U; Jost, PJ; Jilg, S Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
Eur J Haematol. 2020; 104(2):125-137 Doi: 10.1111/ejh.13354 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Hähnel, T; Baldow, C; Guilhot, J; Guilhot, F; Saussele, S; Mustjoki, S; Jilg, S; Jost, PJ; Dulucq, S; Mahon, FX; Roeder, I; Fassoni, AC; Glauche, I Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML.
Cancer Res. 2020; 80(11):2394-2406 Doi: 10.1158/0008-5472.CAN-19-2175
Web of Science PubMed FullText FullText_MUG

 

** Jayavelu, AK; Schnöder, TM; Perner, F; Herzog, C; Meiler, A; Krishnamoorthy, G; Huber, N; Mohr, J; Edelmann-Stephan, B; Austin, R; Brandt, S; Palandri, F; Schröder, N; Isermann, B; Edlich, F; Sinha, AU; Ungelenk, M; Hübner, CA; Zeiser, R; Rahmig, S; Waskow, C; Coldham, I; Ernst, T; Hochhaus, A; Jilg, S; Jost, PJ; Mullally, A; Bullinger, L; Mertens, PR; Lane, SW; Mann, M; Heidel, FH Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.
Nature. 2020; 588(7836):157-163 Doi: 10.1038/s41586-020-2968-3
Web of Science PubMed FullText FullText_MUG

 

** Joensuu, H; Eriksson, M; Sundby Hall, K; Reichardt, A; Hermes, B; Schütte, J; Cameron, S; Hohenberger, P; Jost, PJ; Al-Batran, SE; Lindner, LH; Bauer, S; Wardelmann, E; Nilsson, B; Kallio, R; Jaakkola, P; Junnila, J; Alvegård, T; Reichardt, P Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
JAMA Oncol. 2020; 6(8):1241-1246 Doi: 10.1001/jamaoncol.2020.2091 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Jost, PJ; Vucic, D Regulation of Cell Death and Immunity by XIAP.
JACC-CARDIOVASC INTE. 2020; 13(15): a036426 Doi: 10.1101/cshperspect.a036426
Web of Science FullText FullText_MUG

 

** Jost, PJ; Vucic, D Regulation of Cell Death and Immunity by XIAP.
Cold Spring Harb Perspect Biol. 2020; 12(8): Doi: 10.1101/cshperspect.a036426 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Knop, J; Spilgies, LM; Rufli, S; Reinhart, R; Vasilikos, L; Yabal, M; Owsley, E; Jost, PJ; Marsh, RA; Wajant, H; Robinson, MD; Kaufmann, T; Wong, WW Correction: TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAP.
Cell Death Dis. 2020; 11(1):56-56 Doi: 10.1038/s41419-020-2261-2 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Lampl, S; Janas, MK; Donakonda, S; Brugger, M; Lohr, K; Schneider, A; Manske, K; Sperl, LE; Kläger, S; Küster, B; Wettmarshausen, J; Müller, C; Laschinger, M; Hartmann, D; Hüser, N; Perocchi, F; Schmitt-Kopplin, P; Hagn, F; Zender, L; Hornung, V; Borner, C; Pichlmair, A; Kashkar, H; Klingenspor, M; Prinz, M; Schreiner, S; Conrad, M; Jost, PJ; Zischka, H; Steiger, K; Krönke, M; Zehn, D; Protzer, U; Heikenwälder, M; Knolle, PA; Wohlleber, D Reduced mitochondrial resilience enables non-canonical induction of apoptosis after TNF receptor signaling in virus-infected hepatocytes.
J Hepatol. 2020; 73(6):1347-1359 Doi: 10.1016/j.jhep.2020.06.026
Web of Science PubMed FullText FullText_MUG

 

** Munkhbaatar, E; Dietzen, M; Agrawal, D; Anton, M; Jesinghaus, M; Boxberg, M; Pfarr, N; Bidola, P; Uhrig, S; Höckendorf, U; Meinhardt, AL; Wahida, A; Heid, I; Braren, R; Mishra, R; Warth, A; Muley, T; Poh, PSP; Wang, X; Fröhling, S; Steiger, K; Slotta-Huspenina, J; van, Griensven, M; Pfeiffer, F; Lange, S; Rad, R; Spella, M; Stathopoulos, GT; Ruland, J; Bassermann, F; Weichert, W; Strasser, A; Branca, C; Heikenwalder, M; Swanton, C; McGranahan, N; Jost, PJ MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically.
Nat Commun. 2020; 11(1):4527 Doi: 10.1038/s41467-020-18372-1 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Safi, S; Yamauchi, Y; Hoffmann, H; Weichert, W; Jost, PJ; Winter, H; Muley, T; Beckhove, P Circulating Interleukin-4 Is Associated with a Systemic T Cell Response against Tumor-Associated Antigens in Treatment-Naïve Patients with Resectable Non-Small-Cell Lung Cancer.
Cancers (Basel). 2020; 12(12): Doi: 10.3390/cancers12123496 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Scherr, AL; Mock, A; Gdynia, G; Schmitt, N; Heilig, CE; Korell, F; Rhadakrishnan, P; Hoffmeister, P; Metzeler, KH; Schulze-Osthoff, K; Illert, AL; Boerries, M; Trojan, J; Waidmann, O; Falkenhorst, J; Siveke, J; Jost, PJ; Bitzer, M; Malek, NP; Vecchione, L; Jelas, I; Brors, B; Glimm, H; Stenzinger, A; Grekova, SP; Gehrig, T; Schulze-Bergkamen, H; Jäger, D; Schirmacher, P; Heikenwalder, M; Goeppert, B; Schneider, M; Fröhling, S; Köhler, BC Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer.
Cell Death Dis. 2020; 11(10):875 Doi: 10.1038/s41419-020-03092-7 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Schwaab, J; Naumann, N; Luebke, J; Jawhar, M; Somervaille, TCP; Williams, MS; Frewin, R; Jost, PJ; Lichtenegger, FS; La Rosée, P; Storch, N; Haferlach, T; Horny, HP; Fabarius, A; Haferlach, C; Burchert, A; Hofmann, WK; Cross, NCP; Hochhaus, A; Reiter, A; Metzgeroth, G Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
Am J Hematol. 2020; 95(7):824-833 Doi: 10.1002/ajh.25825 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

** Munkhbaatar, E; Dietzen, M; McGranahan, N; Jost, PJ Dissecting clonal evolution in lung adenocarcinoma identified chromosomal gains on 1q21 implying novel therapeutic targets.
ONCOL RES TREAT. 2020; 43(SUPPL 4):135-135. [Onlinepräsentation]
Web of Science

 

2019

Beiträge in Fachzeitschriften

** Bidola, P; Martins de Souza E Silva, J; Achterhold, K; Munkhbaatar, E; Jost, PJ; Meinhardt, AL; Taphorn, K; Zdora, MC; Pfeiffer, F; Herzen, J A step towards valid detection and quantification of lung cancer volume in experimental mice with contrast agent-based X-ray microtomography.
Sci Rep. 2019; 9(1):1325-1325 Doi: 10.1038/s41598-018-37394-w [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Huemer, F; Melchardt, T; Jansko, B; Wahida, A; Jilg, S; Jost, PJ; Klieser, E; Steiger, K; Magnes, T; Pleyer, L; Greil-Ressler, S; Rass, C; Greil, R; Egle, A Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
Eur J Haematol. 2019; 102(5):437-441 Doi: 10.1111/ejh.13218 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Jilg, S; Hauch, RT; Kauschinger, J; Buschhorn, L; Odinius, TO; Dill, V; Müller-Thomas, C; Herold, T; Prodinger, PM; Schmidt, B; Hempel, D; Bassermann, F; Peschel, C; Götze, KS; Höckendorf, U; Haferlach, T; Jost, PJ Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose.
Exp Hematol Oncol. 2019; 8(10):9-9 Doi: 10.1186/s40164-019-0133-1 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Jilg, S; Rassner, M; Maier, J; Waldeck, S; Kehl, V; Follo, M; Philipp, U; Sauter, A; Specht, K; Mitschke, J; Lange, T; Bauer, S; Jost, PJ; Peschel, C; Duyster, J; Gaiser, T; Hohenberger, P; von Bubnoff, N Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).
Int J Cancer. 2019; 145(8):2292-2303 Doi: 10.1002/ijc.32282
Web of Science PubMed FullText FullText_MUG

 

** Jost, PJ; Höckendorf, U Necroinflammation emerges as a key regulator of hematopoiesis in health and disease.
Cell Death Differ. 2019; 26(1):53-67 Doi: 10.1038/s41418-018-0194-4 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Knop, J; Spilgies, LM; Rufli, S; Reinhart, R; Vasilikos, L; Yabal, M; Owsley, E; Jost, PJ; Marsh, RA; Wajant, H; Robinson, MD; Kaufmann, T; Wong, WW TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAP.
Cell Death Dis. 2019; 10(10):700-700 Doi: 10.1038/s41419-019-1938-x [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Müller, N; Fischer, JC; Yabal, M; Haas, T; Poeck, H; Jost, PJ XIAP deficiency in hematopoietic recipient cells drives donor T-cell activation and GvHD in mice.
Eur J Immunol. 2019; 49(3):504-507 Doi: 10.1002/eji.201847818
Web of Science PubMed FullText FullText_MUG

 

** Riedmann, K; Bassermann, F; Jost, PJ [Kinase inhibitors in oncology : What is new?]
Internist (Berl). 2019; 60(5):540-544 Doi: 10.1007/s00108-019-0577-8
Web of Science PubMed FullText FullText_MUG

 

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

** Horak, P; Heining, C; Kreutzfeldt, S; Heilig, CE; Mohrmann, L; Gieldon, L; Frohlich, M; Uhrig, S; Hubschmann, D; Beck, K; Richter, D; Wolf, S; Pfutze, K; Georg, C; Meissburger, B; Klauschen, F; Ochsenreither, S; Folprecht, G; Siveke, J; Bauer, S; Kindler, T; Brandts, C; Borries, M; von Bubnoff, N; Spiekermann, K; Jost, PJ; Schulze-Osthoff, K; Bitzer, M; Schirmacher, P; von Kalle, C; Schlenk, R; Klink, B; Flutter, B; Weichert, W; Stenzinger, A; Schrock, E; Brors, B; Glimm, H; Frohling, S Clinical relevance of comprehensive genomic analysis in advanced-stage cancers and rare malignancies: Results from the MASTER trial of the German Cancer Consortium
CANCER RES. 2019; 79(13): Doi: 10.1158/1538-7445.AM2019-468
Web of Science FullText FullText_MUG

 

** Pfarr, N; Boxberg, M; Riedmann, K; Jesinghaus, M; Konukiewitz, B; Glimm, H; Jost, PJ; Frohling, S; Weichert, W Detection of the mutation burden status and microsatellite instability by targeted next generation sequencing applying a large gene panel
VIRCHOWS ARCH. 2019; 475: S104-S104.
Web of Science

 

2018

Beiträge in Fachzeitschriften

** Galluzzi, L; Vitale, I; Aaronson, SA; Abrams, JM; Adam, D; Agostinis, P; Alnemri, ES; Altucci, L; Amelio, I; Andrews, DW; Annicchiarico-Petruzzelli, M; Antonov, AV; Arama, E; Baehrecke, EH; Barlev, NA; Bazan, NG; Bernassola, F; Bertrand, MJM; Bianchi, K; Blagosklonny, MV; Blomgren, K; Borner, C; Boya, P; Brenner, C; Campanella, M; Candi, E; Carmona-Gutierrez, D; Cecconi, F; Chan, FK; Chandel, NS; Cheng, EH; Chipuk, JE; Cidlowski, JA; Ciechanover, A; Cohen, GM; Conrad, M; Cubillos-Ruiz, JR; Czabotar, PE; D'Angiolella, V; Dawson, TM; Dawson, VL; De Laurenzi, V; De Maria, R; Debatin, KM; DeBerardinis, RJ; Deshmukh, M; Di Daniele, N; Di Virgilio, F; Dixit, VM; Dixon, SJ; Duckett, CS; Dynlacht, BD; El-Deiry, WS; Elrod, JW; Fimia, GM; Fulda, S; García-Sáez, AJ; Garg, AD; Garrido, C; Gavathiotis, E; Golstein, P; Gottlieb, E; Green, DR; Greene, LA; Gronemeyer, H; Gross, A; Hajnoczky, G; Hardwick, JM; Harris, IS; Hengartner, MO; Hetz, C; Ichijo, H; Jäättelä, M; Joseph, B; Jost, PJ; Juin, PP; Kaiser, WJ; Karin, M; Kaufmann, T; Kepp, O; Kimchi, A; Kitsis, RN; Klionsky, DJ; Knight, RA; Kumar, S; Lee, SW; Lemasters, JJ; Levine, B; Linkermann, A; Lipton, SA; Lockshin, RA; López-Otín, C; Lowe, SW; Luedde, T; Lugli, E; MacFarlane, M; Madeo, F; Malewicz, M; Malorni, W; Manic, G; Marine, JC; Martin, SJ; Martinou, JC; Medema, JP; Mehlen, P; Meier, P; Melino, S; Miao, EA; Molkentin, JD; Moll, UM; Muñoz-Pinedo, C; Nagata, S; Nuñez, G; Oberst, A; Oren, M; Overholtzer, M; Pagano, M; Panaretakis, T; Pasparakis, M; Penninger, JM; Pereira, DM; Pervaiz, S; Peter, ME; Piacentini, M; Pinton, P; Prehn, JHM; Puthalakath, H; Rabinovich, GA; Rehm, M; Rizzuto, R; Rodrigues, CMP; Rubinsztein, DC; Rudel, T; Ryan, KM; Sayan, E; Scorrano, L; Shao, F; Shi, Y; Silke, J; Simon, HU; Sistigu, A; Stockwell, BR; Strasser, A; Szabadkai, G; Tait, SWG; Tang, D; Tavernarakis, N; Thorburn, A; Tsujimoto, Y; Turk, B; Vanden Berghe, T; Vandenabeele, P; Vander Heiden, MG; Villunger, A; Virgin, HW; Vousden, KH; Vucic, D; Wagner, EF; Walczak, H; Wallach, D; Wang, Y; Wells, JA; Wood, W; Yuan, J; Zakeri, Z; Zhivotovsky, B; Zitvogel, L; Melino, G; Kroemer, G Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.
Cell Death Differ. 2018; 25(3):486-541 Doi: 10.1038/s41418-017-0012-4 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Lier, A; Penzel, R; Heining, C; Horak, P; Frohlich, M; Uhrig, S; Budczies, J; Kirchner, M; Volckmar, AL; Hutter, B; Kreutzfeldt, S; Endris, V; Richter, D; Wolf, S; Pfutze, K; Neumann, O; Buchhalter, I; de Oliveira, CMM; Singer, S; Leichsenring, J; Herpel, E; Klauschen, F; Jost, PJ; Metzeler, KH; Schulze-Osthoff, K; Kopp, HG; Kindler, T; Rieke, DT; Lamping, M; Brandts, C; Falkenhorst, J; Bauer, S; Schrock, E; Folprecht, G; Boerries, M; von Bubnoff, N; Weichert, W; Brors, B; Lichter, P; von Kalle, C; Schirmacher, P; Glimm, H; Frohling, S; Stenzinger, A Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience
JCO PRECIS ONCOL. 2018; 2: Doi: 10.1200/PO.18.00171
Web of Science FullText FullText_MUG

 

** Moog, P; Jost, PJ; Büttner-Herold, M Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft.
BMC Nephrol. 2018; 19(1):106-106 Doi: 10.1186/s12882-018-0904-7 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Reidel, V; Kauschinger, J; Hauch, RT; Müller-Thomas, C; Nadarajah, N; Burgkart, R; Schmidt, B; Hempel, D; Jacob, A; Slotta-Huspenina, J; Höckendorf, U; Peschel, C; Kern, W; Haferlach, T; Götze, KS; Jilg, S; Jost, PJ Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.
Oncotarget. 2018; 9(25):17270-17281 Doi: 10.18632/oncotarget.24775 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

** Rinaldetti, S; Pfirrmann, M; Manz, K; Guilhot, J; Dietz, C; Panagiotidis, P; Spiess, B; Seifarth, W; Fabarius, A; Müller, M; Pagoni, M; Dimou, M; Dengler, J; Waller, CF; Brümmendorf, TH; Herbst, R; Burchert, A; Janβen, C; Goebeler, ME; Jost, PJ; Hanzel, S; Schafhausen, P; Prange-Krex, G; Illmer, T; Janzen, V; Klausmann, M; Eckert, R; Büschel, G; Kiani, A; Hofmann, WK; Mahon, FX; Saussele, S Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.
Clin Lymphoma Myeloma Leuk. 2018; 18(4):266-271 Doi: 10.1016/j.clml.2018.02.004 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

** Jilg, S; Hauch, RT; Wahida, A; Kauschinger, J; Buschhorn, L; Odinius, T; Reidel, V; Schmid, B; Hempel, D; Hollein, A; Peschel, C; Bassermann, F; Slotta-Huspenina, J; Hockendorf, U; Jost, PJ Stage-dependent role of pro-necroptotic RIPK1/3 in patients with MDS and CMML
ONCOL RES TREAT. 2018; 41: 94-94.
Web of Science

 

** Muller, N; Fischer, J; Haas, T; Poeck, H; Yabal, M; Jost, PJ RIPK3 as an essential mediator of inflammation and cell death which facilitates IL-17 induction in innate and adaptive T lymphocyte subsets
EUR J IMMUNOL. 2018; 48: 121-121.
Web of Science

 

** Pfarr, N; Boxberg, M; Riedmann, K; Jesinghaus, M; Konukiewitz, B; Glimm, H; Jost, PJ; Frohling, S; Weichert, W Reliability of the detection of the mutation burden status by targeted next generation sequencing applying a large gene panel
ANN ONCOL. 2018; 29:
Web of Science

 

2017

Beiträge in Fachzeitschriften

** Boege, Y; Malehmir, M; Healy, ME; Bettermann, K; Lorentzen, A; Vucur, M; Ahuja, AK; Böhm, F; Mertens, JC; Shimizu, Y; Frick, L; Remouchamps, C; Mutreja, K; Kähne, T; Sundaravinayagam, D; Wolf, MJ; Rehrauer, H; Koppe, C; Speicher, T; Padrissa-Altés, S; Maire, R; Schattenberg, JM; Jeong, JS; Liu, L; Zwirner, S; Boger, R; Hüser, N; Davis, RJ; Müllhaupt, B; Moch, H; Schulze-Bergkamen, H; Clavien, PA; Werner, S; Borsig, L; Luther, SA; Jost, PJ; Weinlich, R; Unger, K; Behrens, A; Hillert, L; Dillon, C; Di Virgilio, M; Wallach, D; Dejardin, E; Zender, L; Naumann, M; Walczak, H; Green, DR; Lopes, M; Lavrik, I; Luedde, T; Heikenwalder, M; Weber, A A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development.
Cancer Cell. 2017; 32(3):342-359 Doi: 10.1016/j.ccell.2017.08.010 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Höckendorf, U; Yabal, M; Jost, PJ Killing AML: RIPK3 leads the way.
Cell Cycle. 2017; 16(1):3-4 Doi: 10.1080/15384101.2016.1232069 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Holch, JW; Metzeler, KH; Jung, A; Riedmann, K; Jost, PJ; Weichert, W; Kirchner, T; Heinemann, V; Westphalen, CB Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
Eur J Cancer. 2017; 82(3):72-79 Doi: 10.1016/j.ejca.2017.05.034
Web of Science PubMed FullText FullText_MUG

 

** Lawlor, KE; Feltham, R; Yabal, M; Conos, SA; Chen, KW; Ziehe, S; Graß, C; Zhan, Y; Nguyen, TA; Hall, C; Vince, AJ; Chatfield, SM; D'Silva, DB; Pang, KC; Schroder, K; Silke, J; Vaux, DL; Jost, PJ; Vince, JE XIAP Loss Triggers RIPK3- and Caspase-8-Driven IL-1β Activation and Cell Death as a Consequence of TLR-MyD88-Induced cIAP1-TRAF2 Degradation.
Cell Rep. 2017; 20(3):668-682 Doi: 10.1016/j.celrep.2017.06.073 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

** Hockendorf, U; Yabal, M; Jost, PJ RIPK3-Dependent Cell Death and Differentiation of Leukemia Initiating Cells Restrict Myeloid Leukemogenesis
ANN HEMATOL. 2017; 96: S50-S50.
Web of Science

 

** Jilg, S; Kauschinger, J; Hauch, RT; Reidel, V; Muller-Thomas, C; Schmidt, B; Hockendorf, U; Peschel, C; Gotze, KS; Jost, PJ Inhibition of Polo-like Kinase 1 effectively induces cell death in MDS, CMML-1/-2 and sAML while sparing the healthy heamatopoiesis
ONCOL RES TREAT. 2017; 40: 179-179.
Web of Science

 

** Jilg, S; Reidel, V; Kauschinger, J; Muller-Thomas, C; Hauch, R; Schauwecker, J; Burkhard, S; Hockendorf, U; Peschel, C; Kern, W; Haferlach, T; Slotta-Huspenina, J; Gotze, KS; Jost, PJ BCL-2 INHIBITION BY ABT-199 POTENTLY INDUCES CELL DEATH IN MDS PROGENITORS DESPITE HIGH-RISK MUTATIONS IN ASXL1, RUNX1, TP53 OR EZH2
LEUKEMIA RES. 2017; 55: S156-S156. Doi: 10.1016/S0145-2126(17)30385-5
Web of Science FullText FullText_MUG

 

** Jost, PJ; Yabal, M; Hockendorf, U Inflammation and cell death controls AML development, phenotype and outcome
ONCOL RES TREAT. 2017; 40: 54-54.
Web of Science

 

** Rinaldetti, S; Pfirrmann, M; Manz, K; Guilhot, J; Panagiotidis, P; Spiess, B; Seifarth, W; Fabarius, A; Pagoni, M; Dimou, M; Dengler, J; Waller, C; Brummendorf, TH; Herbst, R; Burchert, A; Janssen, C; Goebeler, ME; Jost, PJ; Hanzel, S; Schafhausen, P; Prange-Krex, G; Illmer, T; Janzen, V; Klausmann, M; Eckert, R; Buschel, G; Kiani, A; Hofmann, WK; Mahon, FX; Saussele, S IMPACT OF ABCG2, OCT1 AND ABCB1 (MDR1) ON TREATMENT FREE REMISSION IN AN EUROSKI SUBTRIAL
HAEMATOLOGICA. 2017; 102: 74-74. [OPEN ACCESS]
Web of Science

 

2016

Beiträge in Fachzeitschriften

** Engel, K; Rudelius, M; Slawska, J; Jacobs, L; Ahangarian Abhari, B; Altmann, B; Kurutz, J; Rathakrishnan, A; Fernández-Sáiz, V; Brunner, A; Targosz, BS; Loewecke, F; Gloeckner, CJ; Ueffing, M; Fulda, S; Pfreundschuh, M; Trümper, L; Klapper, W; Keller, U; Jost, PJ; Rosenwald, A; Peschel, C; Bassermann, F USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma.
EMBO Mol Med. 2016; 8(8):851-862 Doi: 10.15252/emmm.201506047 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Fernández-Marrero, Y; Spinner, S; Kaufmann, T; Jost, PJ Survival control of malignant lymphocytes by anti-apoptotic MCL-1.
Leukemia. 2016; 30(11):2152-2159 Doi: 10.1038/leu.2016.213
Web of Science PubMed FullText FullText_MUG

 

** Höckendorf, U; Yabal, M; Herold, T; Munkhbaatar, E; Rott, S; Jilg, S; Kauschinger, J; Magnani, G; Reisinger, F; Heuser, M; Kreipe, H; Sotlar, K; Engleitner, T; Rad, R; Weichert, W; Peschel, C; Ruland, J; Heikenwalder, M; Spiekermann, K; Slotta-Huspenina, J; Groß, O; Jost, PJ RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells.
Cancer Cell. 2016; 30(1):75-91 Doi: 10.1016/j.ccell.2016.06.002 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Höckendorf, U; Yabal, M; Jost, PJ RIPK3-dependent cell death and inflammasome activation in FLT3-ITD expressing LICs.
Oncotarget. 2016; 7(36):57483-57484 Doi: 10.18632/oncotarget.11195 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Hrdinka, M; Fiil, BK; Zucca, M; Leske, D; Bagola, K; Yabal, M; Elliott, PR; Damgaard, RB; Komander, D; Jost, PJ; Gyrd-Hansen, M CYLD Limits Lys63- and Met1-Linked Ubiquitin at Receptor Complexes to Regulate Innate Immune Signaling.
Cell Rep. 2016; 14(12):2846-2858 Doi: 10.1016/j.celrep.2016.02.062 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Jilg, S; Reidel, V; Müller-Thomas, C; König, J; Schauwecker, J; Höckendorf, U; Huberle, C; Gorka, O; Schmidt, B; Burgkart, R; Ruland, J; Kolb, HJ; Peschel, C; Oostendorp, RA; Götze, KS; Jost, PJ Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.
Leukemia. 2016; 30(1):112-123 Doi: 10.1038/leu.2015.179
Web of Science PubMed FullText FullText_MUG

 

** Spinner, S; Crispatzu, G; Yi, JH; Munkhbaatar, E; Mayer, P; Höckendorf, U; Müller, N; Li, Z; Schader, T; Bendz, H; Hartmann, S; Yabal, M; Pechloff, K; Heikenwalder, M; Kelly, GL; Strasser, A; Peschel, C; Hansmann, ML; Ruland, J; Keller, U; Newrzela, S; Herling, M; Jost, PJ Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.
Leukemia. 2016; 30(7):1520-1530 Doi: 10.1038/leu.2016.49
Web of Science PubMed FullText FullText_MUG

 

** Wicki, S; Gurzeler, U; Wei-Lynn Wong, W; Jost, PJ; Bachmann, D; Kaufmann, T Loss of XIAP facilitates switch to TNFα-induced necroptosis in mouse neutrophils.
Cell Death Dis. 2016; 7(10):e2422-e2422 Doi: 10.1038/cddis.2016.311 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

** Ahmadova, G; Kreil, S; Jost, PJ; Keller, P; Wolfensberger, N; Maschke, A; Schonberger, B; Haferlach, T; Schwaab, J; Naumann, N; Jahwar, M; Cross, NCP; Fabarius, A; Hofmann, WK; Haferlach, C; Reiter, A; Metzgeroth, G Clinical characteristics and treatment with tyrosine kinase inhibitors in four patients with ETV6-ABL1 positive eosinophilia-associated myeloproliferative neoplasms
ONCOL RES TREAT. 2016; 39: 232-233.
Web of Science

 

** Glauche, I; Liebscher, H; Baldow, C; Kuhn, M; Schulze, P; Haehnel, T; Voskanyan, A; Guilhot, J; Dulucq, S; von Bubnoff, N; Saussele, S; Mustjoki, S; Jost, PJ; Guilhot, F; Mahon, FX; Roeder, I A New Computational Method to Predict Long-Term Minimal Residual Disease and Molecular Relapse after TKI-Cessation in CML
BLOOD. 2016; 128(22): Doi: 10.1182/blood.V128.22.3099.3099 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

** Hockendorf, U; Monica, Y; Peschel, C; Jost, PJ Evasion of Necroptosis and Inflammasome Activation Promotes Myeloid Leukemogenesis
BLOOD. 2016; 128(22): Doi: 10.1182/blood.V128.22.2856.2856 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

** Jilg, S; Kauschinger, J; Reidel, V; Muller-Thomas, C; Hauch, R; Schauwecker, J; Schmidt, B; Hockendorf, U; Peschel, C; Gotze, K; Jost, PJ Combination of 5-Azacytidine and ABT-199 Has a Synergistic Apoptotic Effect in High-Risk MDS/sAML after HMA Failure
BLOOD. 2016; 128(22): Doi: 10.1182/blood.V128.22.4297.4297 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

** Reiter, A; Ahmadova, G; Jawhar, M; Virchis, A; Somervaille, T; Williams, M; Schonberger, B; Frewin, R; Jost, PJ; Maschke, A; Keller, P; Haferlach, T; Naumann, N; Schwaab, J; Fabarius, A; Hofmann, WK; Haferlach, C; Cross, NCP; Metzgeroth, G Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms
BLOOD. 2016; 128(22): Doi: 10.1182/blood.V128.22.3114.3114 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

** Saussele, S; Mahon, FX; Guilhot, J; Dengler, J; Waller, CT; Brummendorf, TH; Herbst, R; Burchert, A; Goebeler, ME; Freunek, G; Prummer, O; Jost, PJ; Prange-Krex, G; Illmer, T; Janzen, V; Schafhausen, P; Klausmann, M; Kiani, A; Eckert, R; de Wit, M; Janssen, C; Muller, MC; Hochhaus, A; Richter, J; Pfirrmann, M Stopping tyrosine kinase inhibitors in a large cohort of European chronic myeloid leukemia (CML) patients: results of the EURO-SKI trial
ONCOL RES TREAT. 2016; 39: 209-209.
Web of Science

 

2015

Beiträge in Fachzeitschriften

** Galluzzi, L; Bravo-San Pedro, JM; Vitale, I; Aaronson, SA; Abrams, JM; Adam, D; Alnemri, ES; Altucci, L; Andrews, D; Annicchiarico-Petruzzelli, M; Baehrecke, EH; Bazan, NG; Bertrand, MJ; Bianchi, K; Blagosklonny, MV; Blomgren, K; Borner, C; Bredesen, DE; Brenner, C; Campanella, M; Candi, E; Cecconi, F; Chan, FK; Chandel, NS; Cheng, EH; Chipuk, JE; Cidlowski, JA; Ciechanover, A; Dawson, TM; Dawson, VL; De Laurenzi, V; De Maria, R; Debatin, KM; Di Daniele, N; Dixit, VM; Dynlacht, BD; El-Deiry, WS; Fimia, GM; Flavell, RA; Fulda, S; Garrido, C; Gougeon, ML; Green, DR; Gronemeyer, H; Hajnoczky, G; Hardwick, JM; Hengartner, MO; Ichijo, H; Joseph, B; Jost, PJ; Kaufmann, T; Kepp, O; Klionsky, DJ; Knight, RA; Kumar, S; Lemasters, JJ; Levine, B; Linkermann, A; Lipton, SA; Lockshin, RA; López-Otín, C; Lugli, E; Madeo, F; Malorni, W; Marine, JC; Martin, SJ; Martinou, JC; Medema, JP; Meier, P; Melino, S; Mizushima, N; Moll, U; Muñoz-Pinedo, C; Nuñez, G; Oberst, A; Panaretakis, T; Penninger, JM; Peter, ME; Piacentini, M; Pinton, P; Prehn, JH; Puthalakath, H; Rabinovich, GA; Ravichandran, KS; Rizzuto, R; Rodrigues, CM; Rubinsztein, DC; Rudel, T; Shi, Y; Simon, HU; Stockwell, BR; Szabadkai, G; Tait, SW; Tang, HL; Tavernarakis, N; Tsujimoto, Y; Vanden Berghe, T; Vandenabeele, P; Villunger, A; Wagner, EF; Walczak, H; White, E; Wood, WG; Yuan, J; Zakeri, Z; Zhivotovsky, B; Melino, G; Kroemer, G Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.
Cell Death Differ. 2015; 22(1):58-73 Doi: 10.1038/cdd.2014.137 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Yabal, M; Jost, PJ XIAP as a regulator of inflammatory cell death: the TNF and RIP3 angle.
Mol Cell Oncol. 2015; 2(1):e964622-e964622 Doi: 10.4161/23723548.2014.964622 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

** Jilg, S; Reidel, V; Muller-Thomas, C; Hockendorf, U; Huberle, C; Peschel, C; Oostendorp, RA; Gotze, KS; Jost, PJ MCL-1 conveys resistance to ABT-199 in primary MDS samples
ONCOL RES TREAT. 2015; 38: 260-260.
Web of Science

 

** Tweedell, RE; Bergmann-Leitner, ES; Tao, DY; King, JG; Robinson, TM; Bingham, K; Lanar, DE; Jost, PJ; Boddey, JA; Dinglasan, RR OPTIMIZED PLASMODIUM FALCIPARUM HEPATOCYTE INFECTION MODEL FACILITATES DRUG AND VACCINE DEVELOPMENT
AM J TROP MED HYG. 2015; 93(4): 290-290.
Web of Science

 

2014

Beiträge in Fachzeitschriften

** Schweneker, K; Clemm, C; Brügel, M; Souvatzoglou, M; Hermisson, M; Schmidt-Graf, F; Zimmer, C; Peschel, C; Jost, PJ Effective long-term treatment with bevacizumab for relapsed glioblastoma: case report and review of the literature.
Exp Hematol Oncol. 2014; 3(16):29-29 Doi: 10.1186/2162-3619-3-29 (- Case Report) [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

** Tao, D; King, JG; Tweedell, RE; Jost, PJ; Boddey, JA; Dinglasan, RR The acute transcriptomic and proteomic response of HC-04 hepatoma cells to hepatocyte growth factor and its implications for Plasmodium falciparum sporozoite invasion.
Mol Cell Proteomics. 2014; 13(5):1153-1164 Doi: 10.1074/mcp.M113.035584 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Wong, WW; Vince, JE; Lalaoui, N; Lawlor, KE; Chau, D; Bankovacki, A; Anderton, H; Metcalf, D; O'Reilly, L; Jost, PJ; Murphy, JM; Alexander, WS; Strasser, A; Vaux, DL; Silke, J cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner.
Blood. 2014; 123(16):2562-2572 Doi: 10.1182/blood-2013-06-510743 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Yabal, M; Müller, N; Adler, H; Knies, N; Groß, CJ; Damgaard, RB; Kanegane, H; Ringelhan, M; Kaufmann, T; Heikenwälder, M; Strasser, A; Groß, O; Ruland, J; Peschel, C; Gyrd-Hansen, M; Jost, PJ XIAP restricts TNF- and RIP3-dependent cell death and inflammasome activation.
Cell Rep. 2014; 7(6):1796-1808 Doi: 10.1016/j.celrep.2014.05.008 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

** Jost, PJ; Yabal, M; Adler, H; Knies, N; Gross, C; Damgaard, RB; Kanegane, H; Peschel, C; Strasser, A; Gross, O; Ruland, J; Gyrd-Hansen, M A Mouse Model for XLP-2 Disease Uncovers a Critical Function for IL-1beta and TNF in Driving Hyper-Inflammation
BLOOD. 2014; 124(21):
Web of Science

 

** Yabal, M; Muller, N; Adler, H; Knies, N; Gross, CJ; Damgaard, RB; Kanegane, H; Ringelhan, M; Kaufmann, T; Heikenwalder, M; Strasser, A; Gross, O; Ruland, J; Peschel, C; Gyrd-Hansen, M; Jost, PJ Aberrant TNF signalling in dendritic cells in the absence of XIAP contributes to X-linked lymphoproliferative disease (XLP-2) by exaggerated necroptosis
ONCOL RES TREAT. 2014; 37: 246-246.
Web of Science

 

2013

Beiträge in Fachzeitschriften

** Damgaard, RB; Fiil, BK; Speckmann, C; Yabal, M; zur Stadt, U; Bekker-Jensen, S; Jost, PJ; Ehl, S; Mailand, N; Gyrd-Hansen, M Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling.
EMBO Mol Med. 2013; 5(8):1278-1295 Doi: 10.1002/emmm.201303090 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Venjakob, AJ; Vogt, S; Stöckl, K; Tischer, T; Jost, PJ; Thein, E; Imhoff, AB; Anetzberger, H Local cooling reduces regional bone blood flow.
J Orthop Res. 2013; 31(11):1820-1827 Doi: 10.1002/jor.22417
Web of Science PubMed FullText FullText_MUG

 

** Vogt, S; Venjakob, AJ; Stöckl, K; Tischer, T; Jost, PJ; Imhoff, AB; Thein, E; Anetzberger, H Evidence of an autoregulatory mechanism of regional bone blood flow at hypotension.
Arch Orthop Trauma Surg. 2013; 133(9):1233-1241 Doi: 10.1007/s00402-013-1801-y
Web of Science PubMed FullText FullText_MUG

 

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

** Jilg, S; Konig, J; Hockendorf, U; Schauwecker, J; Huberle, C; Muller-Thomas, C; Schmidt, B; Burgkart, R; Gotze, K; Kolb, HJ; Peschel, C; Jost, PJ Resistance to apoptosis in high-risk myelodysplastic syndrome can be overcome by pro-apoptotic drug treatment using ABT-737
LEUKEMIA RES. 2013; 37: S29-S30. Doi: 10.1016/S0145-2126(13)70065-1
Web of Science FullText FullText_MUG

 

** Jilg, S; Konig, J; Hockendorf, U; Schauwecker, J; Huberle, C; Muller-Thomas, C; Schmidt, B; Burgkart, R; Kolb, HJ; Gotze, K; Peschel, C; Jost, PJ Pharmacologic intervention with the pro-apoptotic compound ABT-737 potently induces apoptosis in high-risk MDS/sAML bone marrow cells
ONKOLOGIE. 2013; 36: 124-125.
Web of Science

 

2012

Beiträge in Fachzeitschriften

** Damgaard, RB; Nachbur, U; Yabal, M; Wong, WW; Fiil, BK; Kastirr, M; Rieser, E; Rickard, JA; Bankovacki, A; Peschel, C; Ruland, J; Bekker-Jensen, S; Mailand, N; Kaufmann, T; Strasser, A; Walczak, H; Silke, J; Jost, PJ; Gyrd-Hansen, M The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity.
Mol Cell. 2012; 46(6):746-758 Doi: 10.1016/j.molcel.2012.04.014 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Kaufmann, T; Strasser, A; Jost, PJ Fas death receptor signalling: roles of Bid and XIAP.
Cell Death Differ. 2012; 19(1):42-50 Doi: 10.1038/cdd.2011.121 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

** Jost, PJ; Spinner, S; Kelly, G; Herold, M; Yabal, M; Strasser, A; Peschel, C The role of the anti-apoptotic Bcl-2 proteins Bcl-x(L) and Mcl-1 in survival of T-cell Non-Hodgkin's lymphoma
ONKOLOGIE. 2012; 35: 4-4.
Web of Science

 

2011

** Yabal, M; Damgaard, RB; Nachbur, U; Ruland, J; Peschel, C; Strasser, A; Silke, J; Gyrd-Hansen, M; Jost, PJ Inhibition of NOD2 signalling by mutations in the RING domain of XIAP contribute to development of X-linked lymphoproliferative syndrome
ONKOLOGIE. 2011; 34: 113-113.
Web of Science

 

2010

Beiträge in Fachzeitschriften

** Jost, PJ; Kaufmann, T Cancer caused by too much apoptosis--an intriguing contradiction?
Hepatology. 2010; 51(4):1110-1112 Doi: 10.1002/hep.23514 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Vikstrom, I; Carotta, S; Lüthje, K; Peperzak, V; Jost, PJ; Glaser, S; Busslinger, M; Bouillet, P; Strasser, A; Nutt, SL; Tarlinton, DM Mcl-1 is essential for germinal center formation and B cell memory.
Science. 2010; 330(6007):1095-1099 Doi: 10.1126/science.1191793 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

** Jost, PJ; Nachbur, U; Grabow, S; Huang, DC; Bouillet, P; Silke, J; Strasser, A; Kaufmann, T Anti-cancer SMAC-mimetic compounds accelerate hepatocyte cell death upon FAS or TNF-alpha signalling
ONKOLOGIE. 2010; 33: 63-64.
Web of Science

 

2009

Beiträge in Fachzeitschriften

** Bianchi, K; Jost, PJ; Kaufmann, T; Rutkowski, R International EMBO Workshop on 'Model Organisms in Cell Death Research', Obergurgl (Austria).
Cell Death Differ. 2009; 16(8):1180-1183 Doi: 10.1038/cdd.2009.60 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Jost, PJ; Grabow, S; Gray, D; McKenzie, MD; Nachbur, U; Huang, DC; Bouillet, P; Thomas, HE; Borner, C; Silke, J; Strasser, A; Kaufmann, T XIAP discriminates between type I and type II FAS-induced apoptosis.
Nature. 2009; 460(7258):1035-1039 Doi: 10.1038/nature08229 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Kaufmann, T; Jost, PJ; Pellegrini, M; Puthalakath, H; Gugasyan, R; Gerondakis, S; Cretney, E; Smyth, MJ; Silke, J; Hakem, R; Bouillet, P; Mak, TW; Dixit, VM; Strasser, A Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim.
Immunity. 2009; 30(1):56-66 Doi: 10.1016/j.immuni.2008.10.017 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Strasser, A; Jost, PJ; Nagata, S The many roles of FAS receptor signaling in the immune system.
Immunity. 2009; 30(2):180-192 Doi: 10.1016/j.immuni.2009.01.001 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2007

** Jost, PJ; Ruland, J Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.
Blood. 2007; 109(7):2700-2707 Doi: 10.1182/blood-2006-07-025809
Web of Science PubMed FullText FullText_MUG

 

** Jost, PJ; Weiss, S; Ferch, U; Gross, O; Mak, TW; Peschel, C; Ruland, J Bcl10/Malt1 signaling is essential for TCR-induced NF-kappaB activation in thymocytes but dispensable for positive or negative selection.
J Immunol. 2007; 178(2):953-960 Doi: 10.4049/jimmunol.178.2.953 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2005

** Jost, PJ; Stengel, SM; Huber, W; Sarbia, M; Peschel, C; Duyster, J Very severe iron-deficiency anemia in a patient with celiac disease and bulimia nervosa: a case report.
Int J Hematol. 2005; 82(4):310-311 Doi: 10.1532/IJH97.E0505 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

** Jost, PJ; Ferch, U; Weiss, S; Leeder, S; Gross, O; Mak, TW; Peschel, C; Ruland, J Functional and molecular analysis of maturation of thymocytes in Bcl10 or Malt1 deficient mice.
BLOOD. 2005; 106(11): 929A-929A.
Web of Science

 

2003

Beiträge in Fachzeitschriften

** Nieder, C; Jost, PJ; Grosu, AL; Peschel, C; Molls, M Report of a male patient with brain metastases from breast cancer.
Breast. 2003; 12(5):345-347 Doi: 10.1016/s0960-9776(03)00109-7 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

2001

** Jost, PJ; Harbottle, RP; Knight, A; Miller, AD; Coutelle, C; Schneider, H A novel peptide, THALWHT, for the targeting of human airway epithelia.
FEBS Lett. 2001; 489(2-3):263-269 Doi: 10.1016/s0014-5793(00)02236-5 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum